Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Dry eye syndrome can be present in people with autoimmune diseases or other systemic conditions such as diabetes mellitus, Parkinson’s disease, rosacea, rheumatoid arthritis, systemic lupus erythematous, sarcoidosis, Sjögren syndrome, and thyroid disease. Moreover, problems associated with inflammation of the eyelids (blepharitis) or surfaces of the eye can lead to development of dry eyes. Furthermore, certain medications such as antihistamines, antidepressants, decongestants, and blood pressure medications can reduce tear production leading to dry eye symptoms. People who frequently use computer or screens are also at high risk of developing dry eyes, as using screens for a long period can lead to reduced blinking and tear production. Digital device usage has increased significantly in recent years among all age groups, due to extensive use for social and professional purposes.

The global dry eye syndrome treatment market is estimated to be valued at US$ 5,382.6 Million in 2020 and is expected to exhibit a CAGR of 16.2% during the forecast period (2020-2027).

Figure 1. Global Dry Eye Syndrome Treatment Market Value (US$ Mn) & Y-o-Y Growth Analysis, (2016-2027)

Dry Eye Syndrome Treatment  | Coherent Market Insights

Product development and launches by players are expected to drive growth of the dry eye Syndrome Treatment Market.

The development and launch of innovative products for treating dry eye syndrome are expected to drive the dry eye syndrome treatment market growth. For instance, in May 2018, Alcon, a division of Novartis, launched lubricant eye drops called Systane Complete. These are developed using advanced nano-droplet technology allowing fast-acting hydration. In April 2018, Allergan plc. launched TrueTear, the first and only U.S. FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. Moreover, several players are engaged in research and development of medications for treating dry eye syndrome. For instance, in July 2018, Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, announced the initiation of its phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).

Thus, the increasing number of lead candidates which may have the potential to gain FDA approval for further use, is expected to drive growth of the global dry eye Syndrome Treatment Market during the forecast period.

Figure 2. Global Dry Eye Syndrome Treatment Market Share (%), by Product Type, 2020

Dry Eye Syndrome Treatment  | Coherent Market Insights

Global Dry Eye Syndrome Treatment Market: Restraints

Poor accessibility to eye care services in low and middle income countries and the restriction of existing treatment modalities to primary care practitioners are some of the reasons contributing to lack of care for dry eye disease. According to the University of Calabar, Nigeria, the main barriers to eye care in the country include high cost of treatment, lack of trained professionals, and low awareness among the population regarding eye care. Moreover, some people consider dry eye as a symptom rather than a disease and thus, fail to realize the importance of diagnosis and treatment to prevent progression to chronic ocular surface disease.

request-sample

Dry Eye Syndrome Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 5,382.6 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 16.2% 2027 Value Projection: US$ 15,430.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plug, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Supermarket/ Hypermarket, Other Stores, Online Pharmacies.
Companies covered:

Allergan Plc., Novartis AG, Bausch Health Companies, Inc., Johnson and Johnson Vision Care Inc., I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT Pharmaceuticals, Novaliq GmBH, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Growth Drivers:
  • The rising geriatric population and the increasing incidence of autoimmune conditions leading to dry eyes
  • The increasing usage of computers and mobile screens
Restraints & Challenges:
  • Poor accessibility to eye care services in low-and-middle income countries
  • Difficulty in disease diagnosis

Global Dry Eye Syndrome Treatment Market: Impact of Coronavirus (Covid-19) Pandemic

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to the transportation of drugs from one place to another. Players operating in the dry eye syndrome treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing drug formulations due to irregularities in transportation facility. Moreover, distributors of drug products are experiencing irregular demand of products from the retailers.

Global Dry Eye Syndrome Treatment Market- Regional Analysis

On the basis of region, the global dry eye Syndrome Treatment Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the global dry eye syndrome treatment market during the forecast period due to high prevalence of dry eye syndrome in the region. According to a study published by the American Optometric Association in 2017, more than 16 million people were suffering from dry eye syndrome in 2016, globally. High investment in management of dry eye syndrome is another factor driving the growth of the market in the U.S.

Moreover, the rising geriatric population, and the increasing usage of computers and mobile screens are major factors driving growth of the Europe dry eye syndrome treatment market. According to a 2018 study published by the National Center for Biotechnology Information (NCBI), in Europe, by 3 years of age, 68% of children regularly use a computer and 54% undertake online activities. As per the same source, in 2016, it was estimated that the adults in the U.K. spend around 4 hours 45 min per day using digital media.

Figure 3: Global Dry Eye Syndrome Treatment Market Share (%) in Terms of Value, By Region (2020 & 2027)

Dry Eye Syndrome Treatment  | Coherent Market Insights

Global Dry Eye Syndrome Treatment Market- Competitive Landscape

Key players operating in the global dry eye Syndrome Treatment Market are Allergan Plc., Novartis AG, Bausch Health Companies, Inc., Johnson and Johnson Vision Care Inc., I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT pharmaceuticals, Novaliq GmBH, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Dry eye syndrome (DES) is also known as keratisis sicca and keratoconjunctivitis sicca. Patients suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface which is made up of three intertwined layers, a superficial lipid layer produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface.

Market Dynamics

New dry eye therapies are introduced in the market with several new medications in the pipeline seeking approval. Strong product pipeline offers great market growth opportunity as approval of numerous pipeline products is expected to drive the market growth during the forecast period. In August 2018, Sun Pharma received approval for Cequa (cyclosporine ophthalmic solution) 0.09% from the U.S. FDA. The drug is indicated to increase tear production in patients with dry eye disease. Cequa is the only approved cyclosporine product that incorporates a nanomicellar technology and allows better penetration of the active molecule into the ocular tissues. Moreover, in January 2018, Shire plc. received FDA approval for Xiidra (lifitegrast ophthalmic solution 5%), a twice-daily eye drop solution for dry eye disease in adults in Canada. The drug was initially approved by the U.S. FDA in 2016. Thus, product approvals are expected to provide an opportunity for manufacturers to introduce novel therapies in the market.

Key features of the study:

  • This report provides in-depth analysis of the dry eye syndrome treatment market, market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period, 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global dry eye syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study are Allergan Plc., Novartis AG, Bausch Health Companies, Inc., Johnson and Johnson Vision Care Inc., I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT Pharmaceuticals, Novaliq GmBH, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, end user upgrades, market expansion, and marketing tactics
  • The global dry eye syndrome treatment market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for dry eye Syndrome Treatment Market, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the dry eye syndrome treatment market would provide stakeholders vital inputs to make strategic decisions accordingly.

Detailed Segmentation:

  • Global Dry Eye Syndrome Treatment Market, By Product Type :
    • Cyclosporine
    • Oral Corticosteroid
    • Artificial Tears
    • Omega Supplements
    • Punctual Bags
    • Others
  • Global Dry Eye Syndrome Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Supermarket/ Hypermarket
    • Other Stores
    • Online Pharmacies
  • Global Dry Eye Syndrome Treatment Market, By Region:
    • North America
      • By Product Type:
        • Cyclosporine
        • Oral Corticosteroid
        • Artificial Tears
        • Omega Supplements
        • Punctual Bags
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Supermarket/ Hypermarket
        • Other Stores
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product Type:
        • Cyclosporine
        • Oral Corticosteroid
        • Artificial Tears
        • Omega Supplements
        • Punctual Bags
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Supermarket/ Hypermarket
        • Other Stores
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Cyclosporine
        • Oral Corticosteroid
        • Artificial Tears
        • Omega Supplements
        • Punctual Bags
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Supermarket/ Hypermarket
        • Other Stores
        • Online Pharmacies
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type:
        • Cyclosporine
        • Oral Corticosteroid
        • Artificial Tears
        • Omega Supplements
        • Punctual Bags
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Supermarket/ Hypermarket
        • Other Stores
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Product Type:
        • Cyclosporine
        • Oral Corticosteroid
        • Artificial Tears
        • Omega Supplements
        • Punctual Bags
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Supermarket/ Hypermarket
        • Other Stores
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Cyclosporine
        • Oral Corticosteroid
        • Artificial Tears
        • Omega Supplements
        • Punctual Bags
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Supermarket/ Hypermarket
        • Other Stores
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Allergan
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Novartis AG
    • Bausch Health Companies, Inc.
    • Johnson and Johnson Vision Care Inc.
    • I-Med Pharma Inc
    • Santen Pharmaceuticals Co. Ltd.
    • AFT Pharmaceuticals
    • Novaliq GmBH
    • Otsuka Pharmaceutical Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

 “*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Impact Analysis
    • Technological Evolution
    • PEST Analysis
    • Microscope Comparison
    • Porters Analysis
    • COVID-19 Impact Analysis
  4. Global Dry Eye Syndrome Treatment Market, Impact of COVID-19 Pandemic
    • COVID19 Impact
    • Economic Impact
    • Demand and Supply Impact Analysis
  5. Global Dry Eye Syndrome Treatment Market, By Product Type, 2020–2027 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Cyclosporine
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Oral Corticosteroid
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Artificial Tears
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Omega Supplements
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Punctual Bags
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
  6. Global Dry Eye Syndrome Treatment Market, By Distribution Channel, 2020–2027 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Supermarket/ Hypermarket
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Other Stores
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
  7. Global Dry Eye Syndrome Treatment Market, By Region, 2020–2027 (US$ Bn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Region, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Bn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Allergan
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bausch Health Companies, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson and Johnson Vision Care Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • I-Med Pharma Inc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Santen Pharmaceuticals Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AFT Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novaliq GmBH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Otsuka Pharmaceutical Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 27 market data tables and 30 figures on "Dry Eye Syndrome Treatment Market - Global forecast to 2027”

Frequently Asked Questions

The global dry eye syndrome treatment market size is estimated to be valued at US$ 5,382.6 Million in 2020 and is expected to exhibit a CAGR of 16.2% between 2020 and 2027.
The Cyclosporine segment is estimated to account for major market share in 2020, owing to launches and approvals of novel products for the treatment of dry eye syndrome.
Major factors driving growth of the global dry eye syndrome treatment market include product launches, the rising geriatric population, the increasing incidence of autoimmune conditions leading to dry eyes, and the increasing usage of computer and mobile screens.
North America dry eye syndrome treatment market is expected to generate the largest revenue share during the forecast period.
Poor accessibility to eye care services in low-and-middle income countries, and Difficulty in disease diagnosis are the factors restraining the growth of the dry eye syndrome treatment market.
Some of the key players operating in the global dry eye syndrome treatment market are Allergan Plc., Novartis AG, Bausch Health Companies, Inc., Johnson and Johnson Vision Care Inc., I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT Pharmaceuticals, Novaliq GmBH, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner